UPDATE: JPMorgan Assumes Funko (FNKO) at Neutral

Funko (FNKO) PT Raised to $15 at Stifel, Following Earnings

Stifel analyst Drew E. Crum raised the price target on Funko (NASDAQ: FNKO) to $15.00 (from $12.00) while maintaining a Hold rating.

Increasing unusual call option volume: FINV CX QD LC FNKO

Increasing unusual call option volume: FINV CX QD LC FNKO

Pre-Open Stock Movers 03/12: (ANIX) (CRFX) (NVAX) Higher; (MRKR) (RIDE) (POSH) Lower (more...)

Today's Pre-Open Stock Movers

Anixa Biosciences, Inc. (NASDAQ: ANIX) 33.8% HIGHER; announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.

Marker Therapeutics, Inc. (Nasdaq: MRKR) 22.1% LOWER; announced the pricing of an underwritten public offering of 28,572,000 shares of its common stock at a public offering price of $1.75 per... More

Funko (FNKO) PT Raised to $18 at Truist Securities

Truist Securities raised its price target on Funko (NASDAQ: FNKO) to $18.00 (from $13.00) while maintaining a Buy rating.... More

Funko (FNKO) PT Raised to $17 at DA Davidson

DA Davidson analyst Linda Bolton Weiser raised the price target on Funko (NASDAQ: FNKO) to $17.00 (from $7.00) while maintaining a Neutral rating.

The analyst commented, "FNKO reported 4Q20 sales and EBITDA upside surprises, with sales returning to growth (+6%), and the stock was up ~10% after hours.... More

Funko (FNKO) PT Raised to $22 at Piper Sandler

Piper Sandler analyst Erinn Murphy raised the price target on Funko (NASDAQ: FNKO) to $22.00 (from $15.00) while maintaining a Overweight rating.... More

Funko (FNKO) PT Raised to $15.30 at Goldman Sachs

Goldman Sachs analyst Michael Ng raised the price target on Funko (NASDAQ: FNKO) to $15.30 (from $6.60) while maintaining a Neutral rating.... More

After-Hours Stock Movers 03/11: (CFRX) (NVAX) (FNKO) Higher; (MRKR) (POSH) (ULTA) Lower (more...)

Today's After-Hours Stock Movers

ContraFect Corporation (Nasdaq: CFRX) 36.2% HIGHER; has been awarded a cost-share contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). Under the terms of the contract, the Company will receive $9.8 million in initial funding and up to an additional $77.0 million. The initial funding will be used to support ContraFects ongoing pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial)... More

Funko (FNKO) Tops Q4 EPS by 11c

Funko (NASDAQ: FNKO) reported Q4 EPS of $0.25, $0.11 better than the analyst estimate of $0.14. Revenue for the quarter came in at $226.5 million versus the consensus estimate of $195.67 million.

We are pleased to finish the year with strong fourth quarter results, including 6% sales growth, which reflects better... More